AG-1478 (Tyrphostin AG-1478)

Catalog No.S2728 Synonyms: NSC 693255

For research use only.

AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).

AG-1478 (Tyrphostin AG-1478) Chemical Structure

CAS No. 153436-53-4

Selleck's AG-1478 (Tyrphostin AG-1478) has been cited by 75 publications

Purity & Quality Control

Choose Selective EGFR Inhibitors

Other EGFR Products

Biological Activity

Description AG-1478 (Tyrphostin AG-1478, NSC 693255) is a selective EGFR inhibitor with IC50 of 3 nM in cell-free assays, almost no activity on HER2-Neu, PDGFR, Trk, Bcr-Abl and InsR. AG-1478 (Tyrphostin AG-1478) inhibits encephalomyocarditis virus (EMCV) and hepatitis c virus (HCV) by targeting phosphatidylinositol 4-kinase IIIα (PI4KA).
Targets
EGFR [1]
(Cell-free assay)
3 nM
In vitro

AG-1478 is high selective over ErbB2 and PDGFR with IC50 of >100 μM. [1] AG-1478 preferentially inhibits U87MG cells expressing truncated EGFR with IC50 of 8.7 μM, compared to those expressing endogenous wt EGFR or overexpressing exogenous wt EGFR with IC50 of 34.6 μM and 48.4 μM, respectively, and inhibits the DNA synthesis with IC50 of 4.6 μM, 19.67 μM, and 35.2 μM, respectively. AG-1478 also preferentially inhibits the tyrosine kinase activity and autophosphorylation of the ΔEGFR compared to endogenous or overexpressed exogenous wt EGFR. [2] AG-1478 (0.25 μM) abolishes the MAPK activation induced by Ang II, a Ca2+ ionophore as well as EGF but not by a phorbol ester or platelet-derived growth factor-BB in the VSMC. [3] AG-1478 inhibits EGF-induced mitogenesis of the BaF/ERX and LIM1215 cells with IC50 of 0.07 μM and 0.2 μM, respectively. [6] AG1478 is able to inhibit the function of ATP-binding cassette (ABC) transporters such as ABCB1 and ABCG2, with a more pronounced effect on ABCG2. [7]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
U87MG M1XsZmdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NX;vRVg1hjFyMDFOwG0> NH\xSpVFVVOR NFL6T3RKSzVyPUO0MlYh|ryP M4\DcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzh5NUKxOFUoRjh5NUKxOFU9N2F-
U87MG.ΔEGFR M33kNGdzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NWWzS4FRhjFyMDFOwG0> MkPkSG1UVw>? NYLUXm1nUUN3ME24Mlch|ryP MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek85PzV{MUS1K|45PzV{MUS1QE9iRg>?
U87MG.wtEGFR. NUHUZo5JT3Kxd4ToJIlvcGmkaYTvdpkh[XO|YYm= NXHjb4pFhjFyMDFOwG0> NHvPOphFVVOR M{DkS2lEPTB;NEiuOEDPxE1? NWfZN5pnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOEe1NlE1PSd-OEe1NlE1PTxxYU6=
U87MG NEPFTXRMcW6jc3WgZZN{[Xl? M3GxcZ4yODBizszN MmXGSG1UVw>? NWq2[HFvcW6qaXLpeJMhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHl? NEnqOmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi96N{WyNVQ2Lz56N{WyNVQ2RC:jPh?=
U87MG.ΔEGFR MYXLbY5ie2ViYYPzZZk> NWLBTG46hjFyMDFOwG0> NIiyR2ZFVVOR NYfBNVdtcW6qaXLpeJMhTUeIUjD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHl? M17ENVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzh5NUKxOFUoRjh5NUKxOFU9N2F-
U87MG.wtEGFR. NH\m[4NMcW6jc3WgZZN{[Xl? M{f5PZ4yODBizszN MVPEUXNQ Mor1bY5pcWKrdIOgSWdHWiC2eYLvd4lv\SCtaX7hd4Uh[WO2aY\peJk> M4LLR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493Nzh5NUKxOFUoRjh5NUKxOFU9N2F-
HPV 16-immortalized human keratinocytes MWLHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? M365U542OCEQvF2= M2j6SWROW09? Mn75bY5pcWKrdIOgZ4VtdCCpcn;3eIg> Mn3RQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwQTJ6OEe4Nkc,QTJ6OEe4Nlww[T5?
HPV 16-immortalized human keratinocytes MXTGeY5kfGmxbjDhd5NigQ>? MnHzglUxKM7:TR?= Mn;uSG1UVw>? NEPrOmtqdmS3Y3XzJIFzemW|dDDpckB1cGViQ3XscEBEgWOuZR?= NY[wZZU6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxOUK4PFc5Oid-OUK4PFc5OjxxYU6=
HPV 16-immortalized human keratinocytes NEexd29CeG:ydH;zbZMh[XO|YYm= NWLYUIUyhjVyIN88US=> M4\vdGROW09? M1rBe4lv\HWlZYOgZZBweHSxc3nzMi=> MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek86Ojh6N{iyK|46Ojh6N{iyQE9iRg>?
A431 MXrLbY5ie2ViYYPzZZk> M3X6N54yOCEQvF2= MW\EUXNQ NY\LelJQcW6qaXLpeJMhfGinIHLhd4FtKGGwZDDUS2Yu|rFvc4TpcZVt[XSnZDD0fZJwe2mwZTDwbI9{eGixconsZZRqd25ib3[geIhmKEWJRmK= M{X6eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyN{CyNlYzLz5zMEewNlI3OjxxYU6=
MDA-468  M1exUGtqdmG|ZTDhd5NigQ>? MXf+NVAh|ryP M4Pxc2ROW09? NFLyOmZqdmirYnn0d{B1cGViYnHzZYwh[W6mIGTHSk3PuS2|dHnteYxifGWmIIT5do9{cW6nIIDoc5NxcG:{eXzheIlwdiCxZjD0bIUhTUeIUh?= MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODdyMkK2Nkc,OTB5MEKyOlI9N2F-
A431 MkDUSpVv[3Srb36gZZN{[Xl? MVj+NVAh|ryP NWfkVHk2TE2VTx?= M3vUWIlv\HWlZYOgZ4VtdCCleXPs[UBienKnc4S= MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODdyMkK2Nkc,OTB5MEKyOlI9N2F-
MDA-MB-231 M3LJXGtqdmG|ZTDhd5NigQ>? NFTmWHB,PSEQvF2= NFHKdGlFVVOR NXHLNI56cW6qaXLpeJMhTUeIIIP0bY12dGG2ZXSgdIhwe3Cqb4L5cIF1cW:wIH;mJGZMUFJ? MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB|MEG0Okc,OTFyM{CxOFY9N2F-
CNE2 MmPVS5Jwf3SqIHnubIljcXSxcomgZZN{[Xl? MmHMNVAxKM7:TR?= Mmf6SG1UVw>? NXPtUG9jcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGK7IEm4MlQm Mn;oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF2MUCzNlIoRjFzNEGwN|IzRC:jPh?=
CNE2 MnHWT4lv[XOnIHHzd4F6 M3XnZ54yODBizszN M1HwR2ROW09? M3Kz[IlvcGmkaYTzJGVITlJidInyc5NqdmVicHjvd5Bpd3K7bHH0bY9v NV\Lbnh2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0NVA{OjJpPkGxOFExOzJ{PD;hQi=>
CNE2 NXHk[WtUTnWwY4Tpc44h[XO|YYm= MWj+NVAxKM7:TR?= MWDEUXNQ Ml3PTY5pcWKrdIOgUWFRUyCjbnSgRWtVKGGldHn2ZZRqd25? MlnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF2MUCzNlIoRjFzNEGwN|IzRC:jPh?=
CNE2 M1z0cGZ2dmO2aX;uJIF{e2G7 M2j0bp42OCEQvF2= M3zjV2ROW09? NEH4fWxi\m[nY4TzJINmdGxiY4njcIUh\Gm|dILpZpV1cW:w NV;aVGp1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0NVA{OjJpPkGxOFExOzJ{PD;hQi=>
HSC-2 Mof3T4lv[XOnIHHzd4F6 MXu4xsDPxE1? NGXvfWpFVVOR NIXIV4RqdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhTUeIUjDhcoQhSWu2 Mmm1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd4OEmyPFUoRjF5Nki5Nlg2RC:jPh?=
HSC-2 Mnr1RZBweHSxc3nzJIF{e2G7 MXK4xsDPxE1? NVzsfpVjTE2VTx?= NVrUR5NqcW6qaXLpeJMhTmG|LX3l[IlifGWmIHHwc5B1d3Orcx?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzZ6OUK4OUc,OTd4OEmyPFU9N2F-
HEp-2 MVHHdo94fGhiaX7obYJqfG:{eTDhd5NigQ>? NUD5UFFHhjFyIN88US=> NULidVdITE2VTx?= NFvESIlmdmijbnPld{Bwemmmb37pck1qdmS3Y3XkJIdzd3e2aD3pcohq[mm2b4L5 M3jO[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkCyO|QyLz5{MEKwNlc1OTxxYU6=
SubG1 M{nVW2Fxd3C2b4Ppd{Bie3OjeR?= MVH+NVAh|ryP NUGybHg1TE2VTx?= M{\rWoVvcGGwY3XzJI9zcWSxbnnuMYlv\HWlZXSgZZBweHSxc3nz NWHs[WwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNFI4PDFpPkKwNlAzPzRzPD;hQi=>
HEp-2 NH7xfoVHfW6ldHnvckBie3OjeR?= NU\ZfWdFhjFyIN88US=> MlXKSG1UVw>? M4q0SIVvcGGwY3XzJG9zcWSxbnnuMYlv\HWlZXSgRoF5KGGldHn2ZZRqd25uIFLjcE0zKGSnZ4Lh[IF1cW:wIHHu[EBUUVKWMTDpcoFkfGm4YYTpc44> NXfwTJI{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNFI4PDFpPkKwNlAzPzRzPD;hQi=>
H508 M4rDT2dzd3e2aDDpcohq[mm2b4L5JIF{e2G7 NHrGcI9,OSEQvF2= MWXEUXNQ NF63[WJucXSrZ3H0[ZMhS1CILX3l[IlifGWmIFi1NFgh[2WubDDndo94fGh? NIXrUFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWxOFkzPCd-Mk[1NVQ6OjR:L3G+
A431 NGe4OmNCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= M4D5OXRme3SnZDDmc5Ih[W62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzMEBKSzVyPUKw{txO NVXzXXc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWxNFk3PDJpPkG1NVA6PjR{PD;hQi=>
HeLa M3XxXGZ2dmO2aX;uJIF{e2G7 MlnEN|AhdWmwcx?= MnTGTY5pcWKrdHnvckBw\iCHR1\SJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hUGWOYTDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDNyIH3pcpMheHKrb4KgeI8hTUeIIIP0bY12dGG2aX;uJIJ6KFenc4Tldo4h[myxdITpcoc> MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTdzOECyPUc,OjF5MUiwNlk9N2F-
BT-37 NUPwSY9leUiWUzDhd5NigQ>? M4DrbJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?= M33HSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-SH NV7VOVRWeUiWUzDhd5NigQ>? MXvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3TTEBk\Wyucx?= MmnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
NB1643 MnvtdWhVWyCjc4PhfS=> MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MkjQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
OHS-50 NVG5RY9VeUiWUzDhd5NigQ>? NXP4NYRHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=> M1X2WVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
HEK293 MULGeY5kfGmxbjDhd5NigQ>? M1vlZ|EhcHJ? NXzSeJVwUW6qaXLpeIlwdiCxZjDoeY1idiCodXzsJIxmdme2aDDQT21[XDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyC3c3nu[{BGTlNiKEK0O{B1dyB{NUmgdoV{cWS3ZYOpJIF{KHO3YoP0doF1\SCjZoTldkAyKGi{IHL5JIZtfW:{ZYPj[Y5k\SCyb3zhdol7[XSrb36gbY1ufW6xYYPhfUwhU2l;MT64O:69VQ>? MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTl2MUG5N{c,Ojl7NEGxPVM9N2F-
HEK293 NY[xVYt5TnWwY4Tpc44h[XO|YYm= Ml;nNUBpeg>? NEW5UlFKdmirYnn0bY9vKG:oIHj1cYFvKG[3bHygcIVv\3SqIGDLUXlVOSCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KHW|aX7nJGVHWyBqMkS3JJRwKDJ3OTDy[ZNq\HWnczmgZZMhe3Wkc4TyZZRmKGGodHXyJFEhcHJiYomg[ox2d3Knc3PlcoNmKHCxbHHybZpifGmxbjDpcY12dm:jc3H5MEBKSzVyPUG5MlbPxE1? NIm1bHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUm0NVE6Oyd-Mkm5OFEyQTN:L3G+
Assay
Methods Test Index PMID
Western blot EGFR / Neu / p-Tyr ; Shc / PLC-γ1 10931950
Growth inhibition assay Cell viability 25258648
In vivo Administration of AG-1478 blocks phosphorylation of the EGFR at the tumor site and inhibits the growth of A431 xenografts that overexpress the WT EGFR and glioma xenografts expressing the de2-7 EGFR. Even subtherapeutic doses of AG-1478 significantly enhance the efficacy of cytotoxic drugs, with the combination of AG-1478 and temozolomide displaying synergistic antitumor activity against human glioma xenografts. The combination of AG-1478 and an anti-EGFR antibody (mAb 806) displays additive and in some cases synergistic, antitumor activity against tumor xenografts overexpressing the EGFR. [4] The combination of AG-1478 (0.4 mg) with a single dose of 25 μCi 90Y-CHX-A''-DTPA-hu3S193 results in a significant enhancement of efficacy compared with either agent alone. [5]

Protocol (from reference)

Cell Research:

[2]

  • Cell lines: U87MG
  • Concentrations: Dissolved in DMSO, final concentrations ~100 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to different concentrations of AG-1478 for 72 hours in 96-well plates. The effects of AG-1478 on cell growth are examined using an Alamar Blue assay. A 20-μL aliquot of Alamar Blue is added to each well, and its absorbance is determined using a Spectromax Scanning Micro plate Reader. The effects of AG-1478 are expressed as percentage of growth inhibition using untreated cells as the control (0% inhibition). Cellular DNA synthesis is determined using a [3H]thymidine incorporation assay.

Animal Research:

[4]

  • Animal Models: Female BALB/c nu/nu mice inoculated s.c. with A431 or U87MG.Δ2-7 tumor cells
  • Dosages: ~1 mg/kg
  • Administration: Injection i.p. three times per week

Solubility (25°C)

In vitro

DMSO 25 mg/mL
(79.17 mM)
Water Insoluble
Ethanol ''13 mg/mL

Chemical Information

Molecular Weight 315.75
Formula

C16H14ClN3O2

CAS No. 153436-53-4
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles COC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=CC=C3)Cl)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) supplier | purchase AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) cost | AG-1478 (Tyrphostin AG-1478) manufacturer | order AG-1478 (Tyrphostin AG-1478) | AG-1478 (Tyrphostin AG-1478) distributor